Literature DB >> 18178067

Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers.

J J Granizo, B Sádaba, J Honorato, M J Gimenez, D Sevillano, L Aguilar, P Coronel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18178067     DOI： 10.1016/j.ijantimicag.2007.10.024

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  9 in total

1.  Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).

Authors:  Emilio Pérez-Trallero; Jose E Martín-Herrero; Ana Mazón; Celia García-Delafuente; Purificación Robles; Victor Iriarte; Rafael Dal-Ré; Juan García-de-Lomas
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 2.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model.

Authors:  Fabio Cafini; Jose Yuste; Maria-Jose Giménez; David Sevillano; Lorenzo Aguilar; Luis Alou; Elisa Ramos-Sevillano; Martha Torrico; Natalia González; Ernesto García; Pilar Coronel; Jose Prieto
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

4.  Cidal activity of oral third-generation cephalosporins against Streptococcus pneumoniae in relation to cefotaxime intrinsic activity.

Authors:  F Cafini; L Aguilar; L Alou; M J Giménez; D Sevillano; M Torrico; N González; J J Granizo; J E Martín-Herrero; J Prieto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-26       Impact factor: 3.267

5.  Update on the clinical utility and optimal use of cefditoren.

Authors:  José Barberán; Lorenzo Aguilar; María-José Giménez
Journal:  Int J Gen Med       Date:  2012-05-21

Review 6.  Cefditoren in upper and lower community-acquired respiratory tract infections.

Authors:  Francisco Soriano; María-José Giménez; Lorenzo Aguilar
Journal:  Drug Des Devel Ther       Date:  2011-02-09       Impact factor: 4.162

7.  Drug resistance in community-acquired respiratory tract infections: role for an emerging antibacterial.

Authors:  Lorenzo Aguilar; María-José Giménez; José Barberán
Journal:  Infect Drug Resist       Date:  2010-06-18       Impact factor: 4.003

Review 8.  Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults.

Authors:  María-José Giménez; Lorenzo Aguilar; Juan José Granizo
Journal:  Multidiscip Respir Med       Date:  2018-11-02

9.  High protein binding and cidal activity against penicillin-resistant S. pneumoniae: a cefditoren in vitro pharmacodynamic simulation.

Authors:  David Sevillano; Lorenzo Aguilar; Luis Alou; María-José Giménez; Natalia González; Martha Torrico; Fabio Cafini; Asunción Fenoll; Pilar Coronel; José Prieto
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.